← Russell 3000 cross-section

NVAX NOVAVAX INC

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$1.5bn
Revenue TTM
$414m
Net income TTM
$-248m
Free cash flow
Composite score
Sector rank
#1805

Valuation

P / E
EV / EBITDA
EV / sales
2.5
FCF yield
Earnings yield vs 10-yr
-21.51pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-59.8%
EBITDA margin
ROE
129.9%
ROIC
Revenue growth
-61.6%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

The agreement provides for an upfront payment of $30 million, with the potential for up to $500 million in development and sales milestone payments. Sales of Common Stock In August 2023, we entered into an At Market Issuance Sales Agreement (the “August 2023 Sales Agreement”), which allowed us to issue and sell up to $500 million in gross proceeds of shares of our common stock pursuant to a registration statement on Form S-3 (the “Shelf Registration Statement”), and terminated our then-existing At Market Issuance Sales Agreement entered in June 2021. No sales were recorded under the August 2023 Sales Agreement during the three and six months ended June 30, 2026, and 2025. …NOVAVAX INC, 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →